Fisher & Paykel Healthcare receives reimbursement code in Germany


Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH. ASX:FPH).

Fisher & Paykel Healthcare Corporation Limited announced today that it had been granted a health insurance reimbursement code in Germany for its HC221 integrated flow generator-humidifier which is used for the treatment of Obstructive Sleep Apnea (OSA).

The reimbursement code, known as a Hilfsmittelnummer, enables the company’s flow generator to be covered by medical insurance companies in Germany.  Germany is generally considered to be the world’s second largest market for OSA treatment devices.

“Receiving this reimbursement code is an important step in the development of sales of our flow generators in Germany.   We have a well established direct sales operation in Germany, already successfully selling our range of respiratory humidifier systems, neonatal care products and OSA humidifiers and masks”, commented Senior Vice President, Sales & Marketing, Mr Paul Shearer.

Mr Shearer said that while it was still early days, the company expected that receiving the reimbursement  code  would  contribute  to  increased  sales  of  its  integrated  flow  generators  in Germany.

About Fisher & Paykel Healthcare
Fisher  &  Paykel  Healthcare   is  a  leading  designer,  manufacturer   and  marketer  of  heated humidification products and systems for use in respiratory care and the treatment of obstructive sleep apnea.   It also offers an innovative range of patient warming devices and neonatal care products.  The company’s products are sold in over 90 countries worldwide.

For further information contact Michael Daniell CEO on +64 9 574 0161 or Paul Shearer on +64 9
574 0167 at Fisher & Paykel Healthcare Corporation Limited or visit the company’s website at www.fphcare.com

 

About Fisher & Paykel Healthcare

Fisher & Paykel Fisher Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

 

Ends

 

Contact

Investors:

Hayden Brown
Investor Relations Manager
hayden.brown@fphcare.co.nz
+64 (0) 27 807 8073

 

Media:

Karen Knott
Senior Communications Manager
karen.knott@fphcare.co.nz
+64 (0) 21 713 911